

AACR Regulatory Science and Policy Subcommittee

Kenneth C. Anderson, MD, FAACR Subcommittee Chairperson

Program Director and Chief, Division of Hematologic Neoplasia, Kraft Family Professor of Medicine Harvard Medical School, Dana-Farber Cancer Institute Boston, Massachusetts

James L. Abbruzzese, MD, FACP

Chief, Division of Medical Oncology, Department of Medicine, Associate Director for Clinical Research Duke Cancer Institute Durham, North Carolina

Chris Boshoff, MD, PhD

Chief Development Officer Pfizer Oncology New York, New York

William S. Dalton, PhD, MD

Founder and Chief Executive Officer M2Gen Tampa, Florida

Raymond N. DuBois, MD, PhD

Dean, College of Medicine Medical University of South Carolina Charleston, South Carolina

Susan M. Galbraith, MBBCh, PhD

Executive Vice-President, Oncology R&D AstraZeneca Cambridge, England

Judy E. Garber, MD, MPH

Director, Center for Cancer Genetics and Prevention Dana-Farber Cancer Institute Boston, Massachusetts

Levi A. Garraway, MD, PhD

Global Head of Product Development, Chief Medical Officer F. Hoffman-LaRoche Ltd. South San Francisco, California

Richard B. Gaynor, MD

President, Research and Development Neon Therapeutics Cambridge, Massachusetts

William N. Hait, MD, PhD

Global Head of External Innovation Johnson & Johnson Pharmaceutical R&D Raritan, New Jersey

Eric B. Haura, MD

Senior Member Moffitt Cancer Center Tampa, Florida

Roy S. Herbst, MD, PhD


Ensign Professor of Medicine, Associate Director for Translational Research Yale Cancer Center New Haven, Connecticut

Pasi A. Jänne, MD, PhD

Director, Lowe Center for Thoracic Oncology Scientific Director, Belfer Institute for Applied Cancer Science Dana-Farber Cancer Institute Boston, Massachusetts

Chitkala Kalidas, PhD

Vice President, Head Oncology Regulatory Affairs Bayer New York, New York



FINDING CURES TOGETHER*

1401 H Street, NW | Suite 740 Washington, DC 20005 202-898-6499 | 202-898-0966 Fax www.AACR.org | @AACR | Facebook.com/AACR.org

Peter F. Lebowitz, MD, PhD

Senior Vice President, Global Therapeutic Area Head, Oncology Janssen Research and Development, LLC Wayne, Pennsylvania

John E. Leonard, PhD

Senior Vice President, Development Vaccinex Inc. Rochester, New York

Thomas J. Lynch, Jr., MD

President and Director, Fred Hutchinson Cancer Research Center Seattle, Washington

Elaine R. Mardis, PhD

Co-executive Director, Institute for Genomic Medicine Nationwide Children's Hospital Columbus, Ohio

David M. Reese, MD

Vice President, Medical Sciences Amgen Inc. Los Angeles, California

Eric H. Rubin, MD

Vice President and Therapeutic Area Head, Oncology Early Dev. Merck Research Laboratories North Wales, Pennsylvania

Charles L. Sawyers, MD

Chair, Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York, New York

Howard I. Scher, MD

Co-chair, Center for Mechanism Based Therapy Memorial Sloan Kettering Cancer Center New York, New York

Mehdi Shahidi, MD

Corporate Vice President, Global Head of Medicine, Oncology Boehringer Ingelheim Sutton, England

Ellen V. Sigal, PhD

Chairperson and Founder Friends of Cancer Research Washington, D.C.

Suzanne L. Topalian, MD

Professor, Surgery and Oncology, Johns Hopkins University School of Medicine Director, Melanoma Program, Sidney Kimmel Cancer Center Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland

Laura J. van 't Veer, PhD

Professor, Department of Laboratory Medicine UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California

Victor E. Velculescu, MD, PhD

Co-director of Cancer Biology and Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland

Verena Voelter, MD

Head of U.S. Clinical Development and Medical Affairs Novartis Oncology East Hanover, New Jersey